Numb Corp provides a locally administered biologic that blocks pain signaling at the injury site, delivering non‑opioid analgesia for days to weeks with a single injection. The therapy integrates into standard hospital and outpatient injection workflows, helping hospitals, surgical centers, and pain clinics reduce opioid use and improve postoperative pain management.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with acute or postoperative regional pain often rely on systemic opioids or repeated local injections, which can cause side effects, dependence, and require frequent clinical visits. Effective, long-lasting pain relief that targets the injury site without systemic exposure is lacking.
Solution
Numb Corp offers a biologic administered regionally by trained clinicians that interrupts pain signaling at the injury site. A single injection provides non‑opioid analgesia lasting from days to weeks, enabling continuous pain control as patients transition from inpatient to ambulatory settings. By focusing on signal‑level modulation rather than systemic sedation, the therapy reduces opioid use and associated risks while delivering sustained relief. The product is designed for easy integration into existing clinical workflows, requiring only one administration per treatment episode.
Target Audience
Primary customers are hospitals, surgical centers, and pain management clinics that treat patients requiring regional postoperative or injury‑related analgesia.
Features
- Biologic formulation engineered to block pain signals locally without entering systemic circulation
- Single‑dose administration delivering analgesia for multiple days to several weeks
- Compatible with standard injection techniques used by clinicians in hospital and outpatient environments
- Designed for seamless use across inpatient postoperative care and outpatient ambulatory settings
- Non‑opioid mechanism reduces risk of dependence and systemic side effects